Epigenomics AG Provides Update on Progress with US Product Development for Epi proColon
1/13/2011 9:04:45 AM
(BUSINESS WIRE)--Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company’s DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer. This improved product concept is being developed for the US market and as a second generation product for the European and other markets. At the same time, the FDA has set a date in February for a Pre-IDE meeting to discuss with Epigenomics the product concept, its intended use and the clinical data required to support an application for marketing of the product in the US.
comments powered by